Source - RNS
RNS Number : 2354K
Dechra Pharmaceuticals PLC
19 September 2016
 

 

The announcement below replaces an announcement released in error on 15 September 2016 under RNS number 9802J. That announcement should have been released on 19 September 2016 in relation to the grant of awards on 19 September 2016 and not 14 September 2016. In addition, the number of awards for Ian Page have been amended from 73,667 to 73,260 as below.

 

 

 

 

 

19 September 2016

 

Dechra Pharmaceuticals PLC

(the Company)

Director Shareholding

 

 

The Company announces that on 19 September 2016 the following Directors were granted awards over ordinary shares of 1 pence each in the Company in connection with the Dechra Long Term Incentive Plan 2008 (the Plan):

 

Name of individual

Director

Type of award

Number of shares subject to award

Ian Page

Director

LTIP Award - nil cost option

73,260

Tony Griffin

Director

LTIP Award - Conditional award

20,858

 

 

The vesting of all the above awards is subject to the achievement of performance targets.  In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share (EPS) and its Total Shareholder Return (TSR) relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period.  Both the EPS and TSR elements will be subject to an additional Return on Capital Employed (ROCE) performance measure.  If the ROCE performance condition is not met, then the LTIP options will lapse in full.

 

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

Notification of Dealing Form

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Ian Page

 

2.

Reason for the notification

a)

Position/status

Director

 

b)

Initial notification/

amendment

Amendment

Previous notification reference number: 3684.

The notification should have been released on 19 September 2016 in relation to the grant of awards on 19 September 2016 and not 14 September 2016. In addition, the number of awards have been amended from 73,667 to 73,260 as below.

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

N/A

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB0009633180

b)

Nature of the transaction

Grant of nil cost options under the Company's Long Term Incentive Plan

c)

Price(s) and volumes(s)

Price(s)

Nil cost

Volume(s)

73,260

d)

Aggregated information

-   Aggregate volume

-   Price

 

 

N/A

e)

Date of the transaction

2016.09.19

f)

Place of the transaction

Outside a trading venue

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Tony Griffin

 

2.

Reason for the notification

a)

Position/status

Director

 

b)

Initial notification/

amendment

Amendment

Previous notification reference number: 3687.

The notification should have been released on 19 September 2016 in relation to the grant of awards on 19 September 2016 and not 14 September 2016.

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

N/A

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB009633180

b)

Nature of the transaction

Grant of a conditional award under the Company's Long Term Incentive Plan

c)

Price(s) and volumes(s)

Price(s)

Nil cost

Volume(s)

20,858

d)

Aggregated information

-   Aggregate volume

-   Price

 

 

N/A

e)

Date of the transaction

2016.09.19

f)

Place of the transaction

Outside a trading venue

 

For further information, please contact:

 

Suzana Cross, Company Secretary           

Telephone number: 01606 814730

 

 

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHAKCDKQBKDFCD